Donor Spotlight: Janssen Pharmaceuticals

Donor Spotlight: Janssen Pharmaceuticals

Janssen Pharmaceuticals is committed to providing safe and effective medicines and the services and supports that contribute to healthy outcomes. Since 2014, Janssen has been a generous supporter of Thresholds, most recently funding our innovative MindStrong program.

Thresholds’ MindStrong program provides early intervention services to young adults, ages 15-30, with a diagnosis of schizophrenia or schizoaffective disorder who are experiencing first episode psychosis. Dedicated to providing the right supports at the earliest signs of need, MindStrong uses rapid assessment and individualized care planning to address the effects of psychosis on school, work, relationships, independence, and identity development.

MindStrong gives individuals experiencing first episode psychosis the supports needed for a hopeful, successful recovery. We are grateful to Janssen Pharmaceuticals for their generosity – for believing in our work and in the individuals we serve.

Skip to toolbar